William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
Hepatology. 2019 Jan;69(1):329-342. doi: 10.1002/hep.30184. Epub 2018 Dec 27.
Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio-artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild-type large white swine (20 kg-30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24-48 hours after hepatectomy: Group1-standard medical therapy (SMT, n = 6); Group2-SMT plus bio-artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3-SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200-g group survived to 90 hours (P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200-g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200-g group compared with the SMT (P < 0.01) and 0-g (P < 0.01) groups. Ki-67 staining showed increased positive staining at 48 hours following hepatectomy (P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
急性肝衰竭(ALF)是一种灾难性的疾病,可能发生在大肝切除术后。本研究旨在确定球形储液器生物人工肝(SRBAL)对肝切除术后 ALF 猪的存活率、血清化学和肝再生的影响。野生型大白猪(20-30kg)行颅内压(ICP)探头放置,然后行 85%肝切除术。行计算机断层扫描(CT)体积测量以测量切除范围,并在肝切除后 48 小时评估剩余肝脏的再生情况。根据肝切除术后 24-48 小时的治疗方法,将动物随机分为三组:组 1-标准治疗(SMT,n=6);组 2-SMT 加无肝细胞的生物人工肝治疗(0g,n=6);和组 3-SMT 加 200g 原代猪肝细胞球体的 SRBAL 治疗(200g,n=6)。主要终点是肝切除术后 90 小时的存活率。死亡等效定义为无反应性 4 级肝性脑病或 ICP 大于 20mmHg,伴有脑疝的临床证据。两组(SMT 和 0g)对照组的所有动物在肝切除术后 51 小时前均达到死亡等效。200g 组 6 只动物中有 5 只存活至 90 小时(P<0.01)。200g 组的平均氨、ICP 和国际标准化比值均显著降低。肝切除术后 48 小时的 CT 体积测量显示,与 SMT(P<0.01)和 0g(P<0.01)组相比,200g 组的体积再生增加。Ki-67 染色显示肝切除术后 48 小时阳性染色增加(P<0.01)。结论:SRBAL 提高了肝切除术后 ALF 的存活率,降低了氨,并加速了肝脏再生。存活率的提高与 SRBAL 治疗的神经保护作用有关。这些有利的结果证明了 SRBAL 的进一步临床测试是合理的。